metabolism via multiple pathways can also be a contributing factor. Some PGD 2 metabolites are thought to be biologically inactive, and the authors of the highlighted paper (12) observed that the hypothermic activity disappeared when stock solutions of PGD 2 were stored for > 3 wk at -80°C. Other metabolites, including several PGs of the J series with a cyclopentenone structure, are biologically active and, moreover, can affect body temperature. For example, 15-deoxy-Δ 12, 14 -PGJ 2 has been reported to be both antipyretic (18) (29) and be site-specific within the brain (36) , even though the current knowledge about specific sites and mechanisms of the central action of PGD 2 is sketchy. It was thought originally that its receptor (DP, presently known as DP1) is widely distributed throughout the brain, as mentioned in the highlighted paper (12). However, more recent studies with a specific antibody have shown that DP1 immunoreactivity is concentrated in the limited area of leptomeninges of the basal forebrain, where it is often co-localized with lipocalin PGD synthase (17) . This area is in close proximity to the ventrolateral preoptic area (a "sleep center"), and the DP1 receptor in the subarachnoid space of the basal forebrain is thought to trigger the effects of PGD 2 on sleep (8). In addition to DP1, PGD 2 can also act through a distinct receptor type, DP2 (also known as the chemoattractant receptor-homologous molecule expressed on T-helper type 2 cells, or CRTH2) and through several other prostanoid receptors, perhaps different receptors in different species (34) , as well as via a non-receptor-mediated mechanism.
An important methodological issue that cannot be neglected is that the thermoregulatory effect of a compound often strongly depends on the ambient temperature, especially in small rodents. Many adrenergic compounds (39) , drugs of abuse (19), lipopolysaccharide (LPS) (33) , platelet-activating factor (10), and other substances cause hyperthermia in a thermoneutral environment but hypothermia under subneutral conditions. It is, therefore, critical to conduct thermophysiological experiments in rats and mice at a tightly controlled ambient temperature. It is also important to determine whether this temperature is neutral, subneutral, or supraneutral in each experimental setup, because the thermoneutral zone for the same animal in different setups varies widely, depending on several physical factors that affect heat exchange between the animal and its environment (25). One way to determine whether the conditions in a given setup are thermally neutral, subneutral, or supraneutral is by assessing tail skin blood flow, e.g., by thermometry or thermography (25), and several laboratories now use this approach for experiments in rats (1, 4) and mice (27) . From this point of view, the work of Krall et al. (12) is impeccable. In addition to determining the thermoneutral zone in their setup and using properly characterized thermal conditions, the authors also took an important precautionary step in making all injections through preimplanted cannulas, without touching the animals, thus minimizing the associated stress and avoiding stress hyperthermia. Stress hyperthermia due to drug administration has been shown to strongly affect thermal responses. For example, it can mask the early febrile phase and modify the later phases of LPS fever (24) . Because the physiological experiments of Krall et al. (12) were conducted expertly, their study leaves little doubt that PGD 2 can decrease body temperature in rats, at least under some conditions.
Besides decreasing body temperature, PGD 2 is thought to induce sleep (8), increase food intake (21) , and cause analgesia (23) (Fig. 1) . Interestingly, these effects are the exact opposite of those produced by the fever mediator, PGE 2 , which is generally thought to cause wakefulness (8), decrease food intake (20) , and induce hyperalgesia (28) . Remarkably, these PGE 2 -and PGD 2 -mediated responses form distinct patterns that can be seen, respectively, during the first phase of LPS fever, which is mediated by PGE 2 (2, 31) , and during LPS hypothermia, which is thought to be mediated by PGD 2 (36) . We have called these two patterns the early and the late sickness syndromes, respectively, and proposed that they represent two different, sequential stages of the sickness syndrome (26) . As a general rule, the early phase syndrome develops in a previously healthy organism, at the onset of its response to an infection. The late phase syndrome occurs when the organism is already exhausted by the preceding early phase syndrome, weakened by a preexisting pathology, or exposed to a severe, damaging homeostatic challenge. The biological significance of the early phase syndrome is the signaling of the pathogenic challenge (hyperalgesia), recruiting active defense mechanisms (fever), and securing the means (wakefulness, hypertension, generalized motor agitation) for the active search of the optimal environment (conditions for behavioral thermoregulation, sufficient water supply, protection from predators, etc.) for fighting the beginning malady. Manifestations of sickness during the late phase syndrome change drastically.
The pain associated with damage loses its signaling function and starts to contribute to morbidity; consequently, hyperalgesia changes to hypoalgesia. Costly energy consumption during the early phase syndrome, decreased energy supply (e.g., due to the development of adaptive anorexia), and pathological energy expenditure (inefficient In conclusion, whereas the effects of PGE 2 are those occurring when energy is readily available, the highlighted study from the laboratories of Alex Steiner and Carlos 
